雷帕鸣的价格

Kidney transplantation is the most ideal treatment when both kidneys have lost function. For kidney transplant patients, postoperative rejection is the biggest concern. This may mean that the surgical treatment fails and the patient cannot survive long-term. (Sirolimus tablets) is an oral drug used to prevent organ rejection in patients aged 13 or above who have received kidney transplants. It was approved by the US FDA in September 1999. In 2003, Rapamin was launched in China and has been used to treat kidney transplant patients with remarkable results.

The manufacturer of the original drug Rapamin in China is Pfizer of the United States. We all know that the price of the original drug is usually relatively high. However, we have learned that the Indian Biocon version of Rapamin is currently relatively low-priced on the market. The specification is 1mg*10 tablets and the price is around $200. Patients can go to regular local pharmacies in India to buy it. If it is inconvenient to go abroad, they can also consult the Medical Companion Travel Overseas Medical Consulting Service Company to learn about the formal purchase method.

Biocon India was established in 1978, and its chairman is Ms. Kiran Sujishaw, an entrepreneur from Ireland and India. Over the past few decades, Biocon has successfully evolved into an emerging global biopharmaceutical company, serving partners and customers in more than 75 countries and regions. The company's research and development focuses on prevention, palliation and treatment, and its medicines improve the lives of millions of patients in more than 120 countries by connecting them to life-saving treatments and relief.

Biocan in India is cheap and has basically the same therapeutic effect as the original drug. In clinical trials, Rapamin can also reduce the incidence of non-melanoma skin cancer after kidney transplantation. In addition, rapamycin has also achieved good anti-rejection effects after heart transplantation, lung transplantation, corneal transplantation and other transplants, but the therapeutic concentration has not been reported.

Recommended related hot articles: /newsDetail/86844.html